Nanjing Leads Biolabs FY2025 operating loss narrows 29.8% to RMB211 million; revenue rises to RMB177 million

Reuters03-27

Nanjing Leads Biolabs FY2025 operating loss narrows 29.8% to RMB211 million; revenue rises to RMB177 million

Nanjing Leads Biolabs published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB177.3 million.
Research and development costs rose 55.7% to RMB289.1 million, driven by higher CMC milestone expenses tied to preparation for the LBL-024 BLA submission, as well as increased clinical development and preclinical spending.
Administrative expenses fell 5.7% to RMB82.7 million, mainly due to lower share-based compensation, partly offset by higher listing and compliance-related costs.
Loss for the year narrowed 29.8% to RMB211.4 million.
Pipeline updates included completion of patient enrollment in August 2025 for the pivotal registrational trial of LBL-024 in 3L+ EP-NEC in China, with a pre-BLA submission planned for Q2 2026 and a BLA submission targeted for Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12072183), on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622841469?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 17:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622841469","market":"fut","top_or_hot":-1,"title":"Nanjing Leads Biolabs FY2025 operating loss narrows 29.8% to RMB211 million; revenue rises to RMB177 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nanjing Leads Biolabs FY2025 operating loss narrows 29.8% to RMB211 million; revenue rises to RMB177 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Nanjing Leads Biolabs published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB177.3 million.\n        </li>\n<li>\n          Research and development costs rose 55.7% to RMB289.1 million, driven by higher CMC milestone expenses tied to preparation for the LBL-024 BLA submission, as well as increased clinical development and preclinical spending.\n        </li>\n<li>\n          Administrative expenses fell 5.7% to RMB82.7 million, mainly due to lower share-based compensation, partly offset by higher listing and compliance-related costs.\n        </li>\n<li>\n          Loss for the year narrowed 29.8% to RMB211.4 million.\n        </li>\n<li>\n          Pipeline updates included completion of patient enrollment in August 2025 for the pivotal registrational trial of LBL-024 in 3L+ EP-NEC in China, with a pre-BLA submission planned for <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026 and a BLA submission targeted for Q3 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12072183), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nanjing Leads Biolabs FY2025 operating loss narrows 29.8% to RMB211 million; revenue rises to RMB177 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNanjing Leads Biolabs FY2025 operating loss narrows 29.8% to RMB211 million; revenue rises to RMB177 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 17:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nanjing Leads Biolabs FY2025 operating loss narrows 29.8% to RMB211 million; revenue rises to RMB177 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Nanjing Leads Biolabs published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB177.3 million.\n        </li>\n<li>\n          Research and development costs rose 55.7% to RMB289.1 million, driven by higher CMC milestone expenses tied to preparation for the LBL-024 BLA submission, as well as increased clinical development and preclinical spending.\n        </li>\n<li>\n          Administrative expenses fell 5.7% to RMB82.7 million, mainly due to lower share-based compensation, partly offset by higher listing and compliance-related costs.\n        </li>\n<li>\n          Loss for the year narrowed 29.8% to RMB211.4 million.\n        </li>\n<li>\n          Pipeline updates included completion of patient enrollment in August 2025 for the pivotal registrational trial of LBL-024 in 3L+ EP-NEC in China, with a pre-BLA submission planned for <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026 and a BLA submission targeted for Q3 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12072183), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL8jwpM6:1","article_id":"2622841469","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622841469","pubTimestamp":1774602109,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nanjing Leads Biolabs published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB177.3 million.Research and development costs rose 55.7% to RMB289.1 million, driven by higher CMC milestone expenses tied to preparation for the LBL-024 BLA submission, as well as increased clinical development and preclinical spending.Administrative expenses fell 5.7% to RMB82.7 million, mainly due to lower share-based compensation, partly offset by higher listing and compliance-related costs.Loss for the year narrowed 29.8% to RMB211.4 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B","BK1161":"生物科技","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元"},"translate_title":"南京Leads Biolabs 2025财年营业亏损收窄29.8%至人民币2.11亿元；收入增至人民币1.77亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":0.9},"content_text":"Nanjing Leads Biolabs FY2025 operating loss narrows 29.8% to RMB211 million; revenue rises to RMB177 million\n    \n\n\n          Nanjing Leads Biolabs published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB177.3 million.\n        \n\n          Research and development costs rose 55.7% to RMB289.1 million, driven by higher CMC milestone expenses tied to preparation for the LBL-024 BLA submission, as well as increased clinical development and preclinical spending.\n        \n\n          Administrative expenses fell 5.7% to RMB82.7 million, mainly due to lower share-based compensation, partly offset by higher listing and compliance-related costs.\n        \n\n          Loss for the year narrowed 29.8% to RMB211.4 million.\n        \n\n          Pipeline updates included completion of patient enrollment in August 2025 for the pivotal registrational trial of LBL-024 in 3L+ EP-NEC in China, with a pre-BLA submission planned for Q2 2026 and a BLA submission targeted for Q3 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12072183), on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622841469","isCrawlerRequest":true}